This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Launching in 2022, its availability will be expanded to the global market
Subscribe To Our Newsletter & Stay Updated
